Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06514378
PHASE1

Safety of Endobronchial Mesenchymal Stromal Cells in the Treatment of Chronic Lung Allograft Dysfunction

Sponsor: Instituto De Investigación Sanitaria Puerta De Hierro-Segovia De Arana

View on ClinicalTrials.gov

Summary

Lung transplantation is the only therapeutic alternative for more and more patients with respiratory diseases in their most advanced stages. The most limiting factor to achieve long term survival si chronic lung allograft dysfunction, a multifactorial disease without an effective treatment. The immunomodulatory capacity of mesenchymal stem cells enables them to be a potential therapeutic agent for this condition. The objective of this study is to assess the safety of endobronchial administration of allogeneic MSCs in patients with chroniclung allograft dysfunction.

Official title: An Open Label, Randomised, Controlled Clinical Trial to Asses the Safety of Endobronchial Administration of Allogneic Mesenchymal Stromal Cells in Patients With Lung Trasplant Chronic Rejection: Endosclad Study.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-09-19

Completion Date

2026-03-31

Last Updated

2024-07-26

Healthy Volunteers

No

Interventions

BIOLOGICAL

Mesenchymal stem cells

Endobronchial administration of 10⁶ MSCs/kg in each transplanted lung, 4 weeks apart.

Locations (1)

Hospital Universitario Puerta de Hierro Majadahonda

Madrid, Spain